The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer

[1]  K. Matsushima,et al.  A Candidate for Cancer Gene Therapy: MIP-lα Gene Transfer to an Adenocarcinoma Cell Line Reduced T\imorigenicity and Induced Protective Immunity in Immunocompetent Mice , 1996, Pharmaceutical Research.

[2]  M. Kieny,et al.  Tumor gene therapy by MVA-mediated expression of T-cell–stimulating antibodies , 2002, Cancer Gene Therapy.

[3]  R. Figlin,et al.  Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. , 2001, Human gene therapy.

[4]  P. Leroy,et al.  Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: Induction of CD8+ T-cell immunity and NK activity , 2001, Cancer Gene Therapy.

[5]  S. Jameson,et al.  IL-12 Enhances CD8 T Cell Homeostatic Expansion1 , 2001, The Journal of Immunology.

[6]  J. Schlom,et al.  Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. , 2001, Cancer research.

[7]  C. H. Park,et al.  Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. , 2001, Human gene therapy.

[8]  Lieping Chen,et al.  IL-12 gene therapy for cancer: in synergy with other immunotherapies. , 2001, Trends in immunology.

[9]  M. Hitt,et al.  Combined CXC chemokine and interleukin-12 gene transfer enhances antitumor immunity , 2001, Gene Therapy.

[10]  G. Cauet,et al.  Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach , 2001, Cancer Gene Therapy.

[11]  H. Okamura,et al.  Interleukin-18 regulates both Th1 and Th2 responses. , 2001, Annual review of immunology.

[12]  P. Musiani,et al.  The Combined Action of IL-15 and IL-12 Gene Transfer Can Induce Tumor Cell Rejection Without T and NK Cell Involvement1 , 2000, The Journal of Immunology.

[13]  M. Glennie,et al.  Clinical trials of antibody therapy. , 2000, Immunology today.

[14]  N. Glaichenhaus,et al.  The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  P. Leroy,et al.  In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. , 2000, Cancer research.

[16]  D. Allen,et al.  Targeted macrophage cytotoxicity using a nonreplicative live vector expressing a tumor-specific single-chain variable region fragment. , 2000, Human gene therapy.

[17]  S. Thung,et al.  Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  R. Gonzalez,et al.  Clinical Protocol: A Phase I Study Using Direct Combination DNA Injections for the Immunotherapy of Metastatic Melanoma , 2000 .

[19]  Lieping Chen,et al.  Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model. , 2000, Journal of the National Cancer Institute.

[20]  R. Crystal,et al.  Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. , 2000, The Journal of clinical investigation.

[21]  J. Prieto,et al.  Intratumoral Coinjection of Two Adenoviruses, One Encoding the Chemokine IFN-γ-Inducible Protein-10 and Another Encoding IL-12, Results in Marked Antitumoral Synergy1 , 2000, The Journal of Immunology.

[22]  K. Cornetta,et al.  The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. , 2000, Journal of immunology.

[23]  A. Baron,et al.  A phase I study using direct combination DNA injections for the immunotherapy of metastatic melanoma. University of Colorado Cancer Center Clinical Trial. , 2000, Human gene therapy.

[24]  M. Kurimoto,et al.  Interleukin‐18 acts as an angiogenesis and tumor suppressor , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  F. Paillard.  Cytokine and chemokine: a stimulating couple. , 1999, Human gene therapy.

[26]  F. Graham,et al.  Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. , 1999, Human gene therapy.

[27]  S. Gallinger,et al.  Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial , 1999, Gene Therapy.

[28]  R. Rees,et al.  Cells and cytokines in immunotherapy and gene therapy of cancer. , 1999, Critical reviews in oncogenesis.

[29]  J. Teruya-Feldstein,et al.  Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. , 1999, Blood.

[30]  W. Muller,et al.  Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors , 1998, Gene Therapy.

[31]  M. Herold,et al.  Release of chemoattractants for human monocytes from endothelial cells by interaction with neutrophils. , 1998, Cardiovascular research.

[32]  M. Lusky,et al.  In Vitro and In Vivo Biology of Recombinant Adenovirus Vectors with E1, E1/E2A, or E1/E4 Deleted , 1998, Journal of Virology.

[33]  M. Lotze,et al.  Interleukin-7 (IL-7) knockout mice. Implications for lymphopoiesis and organ-specific immunity. , 1998, International reviews of immunology.

[34]  F. Graham,et al.  Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. Sherry,et al.  A mechanism for selective recruitment of CD8 T cells into B7-1-transfected plasmacytoma: role of macrophage-inflammatory protein 1alpha. , 1997, Journal of immunology.

[36]  M. Hitt,et al.  Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. , 1996, Human gene therapy.

[37]  S. Burdach,et al.  Combined chemokine and cytokine gene transfer enhances antitumor immunity , 1996, Nature Medicine.

[38]  D. Goeddel,et al.  RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. , 1996, Human gene therapy.

[39]  M. Mehtali,et al.  Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli , 1996, Journal of virology.

[40]  L. Zitvogel,et al.  Interleukin‐12 and B7.1 co‐stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors , 1996, European journal of immunology.

[41]  A. Angiolillo,et al.  Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. , 1996, Blood.

[42]  A. Pileri,et al.  Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2. , 1996, Leukemia & lymphoma.

[43]  S. H. van der Burg,et al.  An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. , 1995, Human immunology.

[44]  G. Haas,et al.  Synergy of radiation therapy and immunotherapy in murine renal cell carcinoma. , 1992, The Journal of urology.

[45]  T. Fahey,et al.  Macrophage inflammatory protein 1 modulates macrophage function. , 1992, Journal of immunology.

[46]  V. Neuhoff,et al.  Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G‐250 and R‐250 , 1988, Electrophoresis.